Literature DB >> 12408183

Phenylketonuria in adulthood: a collaborative study.

R Koch1, B Burton, G Hoganson, R Peterson, W Rhead, B Rouse, R Scott, J Wolff, A M Stern, F Guttler, M Nelson, F de la Cruz, J Coldwell, R Erbe, M T Geraghty, C Shear, J Thomas, C Azen.   

Abstract

During 1967-1983, the Maternal and Child Health Division of the Public Health Services funded a collaborative study of 211 newborn infants identified on newborn screening as having phenylketonuria (PKU). Subsequently, financial support was provided by the National Institute of Child Health and Human Development (NICHD). The infants were treated with a phenylalanine (Phe)-restricted diet to age 6 years and then randomized either to continue the diet or to discontinue dietary treatment altogether. One hundred and twenty-five of the 211 children were then followed until 10 years of age. In 1998, NICHD scheduled a Consensus Development Conference on Phenylketonuria and initiated a study to follow up the participants from the original Collaborative Study to evaluate their present medical, nutritional, psychological, and socioeconomic status. Fourteen of the original clinics (1967-1983) participated in the Follow-up Study effort. Each clinic director was provided with a list of PKU subjects who had completed the original study (1967-1983), and was asked to evaluate as many as possible using a uniform protocol and data collection forms. In a subset of cases, magnetic resonance imaging and spectroscopy (MRI/MRS) were performed to study brain Phe concentrations. The medical evaluations revealed that the subjects who maintained a phenylalanine-restricted diet reported fewer problems than the diet discontinuers, who had an increased rate of eczema, asthma, mental disorders, headache, hyperactivity and hypoactivity. Psychological data showed that lower intellectual and achievement test scores were associated with dietary discontinuation and with higher childhood and adult blood Phe concentrations. Abnormal MRI results were associated with higher brain Phe concentrations. Early dietary discontinuation for subjects with PKU is associated with poorer outcomes not only in intellectual ability, but also in achievement test scores and increased rates of medical and behavioural problems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408183     DOI: 10.1023/a:1020158631102

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

1.  Comments on the neuropathology of phenylketonuria.

Authors:  C A Dyer
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

2.  Influence of phenylalanine intake on phenylketonuria.

Authors:  H BICKEL; J GERRARD; E M HICKMANS
Journal:  Lancet       Date:  1953-10-17       Impact factor: 79.321

3.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  'Broad-range' DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene.

Authors:  P Guldberg; F Güttler
Journal:  Nucleic Acids Res       Date:  1994-03-11       Impact factor: 16.971

5.  Blood-brain phenylalanine relationships in persons with phenylketonuria.

Authors:  R Koch; R Moats; F Guttler; P Guldberg; M Nelson
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

6.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  S Kure; D C Hou; T Ohura; H Iwamoto; S Suzuki; N Sugiyama; O Sakamoto; K Fujii; Y Matsubara; K Narisawa
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

7.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

Authors:  E Kayaalp; E Treacy; P J Waters; S Byck; P Nowacki; C R Scriver
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

8.  Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine.

Authors:  H K Berry; M K Bofinger; M M Hunt; P J Phillips; M B Guilfoile
Journal:  Pediatr Res       Date:  1982-09       Impact factor: 3.756

9.  Intellectual development in 12-year-old children treated for phenylketonuria.

Authors:  C G Azen; R Koch; E G Friedman; S Berlow; J Coldwell; W Krause; R Matalon; E McCabe; M O'Flynn; R Peterson
Journal:  Am J Dis Child       Date:  1991-01

10.  Collaborative study of children treated for phenylketonuria: study design.

Authors:  M Williamson; J C Dobson; R Koch
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

View more
  57 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Living with phenylketonuria: perspectives of patients and their families.

Authors:  C Bilginsoy; N Waitzman; C O Leonard; S L Ernst
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 3.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

4.  Regulation of M2-type pyruvate kinase mediated by the high-affinity IgE receptors is required for mast cell degranulation.

Authors:  H Ryu; J K L Walker; S Kim; N Koo; L S Barak; T Noguchi; B Y Kang; K-M Kim
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 5.  Genetic screening.

Authors:  Wylie Burke; Beth Tarini; Nancy A Press; James P Evans
Journal:  Epidemiol Rev       Date:  2011-06-27       Impact factor: 6.222

6.  Neurobehavioral problems associated with phenylketonuria.

Authors:  Steven D Targum; William Lang
Journal:  Psychiatry (Edgmont)       Date:  2010-12

7.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

8.  Management of adult patients with phenylketonuria: survey results from 24 countries.

Authors:  Friedrich K Trefz; Francjan J van Spronsen; Anita MacDonald; François Feillet; Ania C Muntau; Amaya Belanger-Quintana; Alberto Burlina; Mübeccel Demirkol; Marcello Giovannini; Christoph Gasteyger
Journal:  Eur J Pediatr       Date:  2014-12-06       Impact factor: 3.183

Review 9.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

Review 10.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.